Close Menu

NEW YORK (Precision Oncology News) – Two studies presented at the American Society of Clinical Oncology annual meeting last week addressed open questions on the use of breast cancer molecular recurrence risk tests for women with early-stage hormone receptor-positive tumors. While one study explored the combination of Genomic Health's Oncotype DX test with clinical risk information, the other reported on the ability of Biotheranostics' Breast Cancer Index test to predict benefit from extended endocrine therapy.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Nov
18
Sponsored by
Mission Bio

This webinar will outline the results of a study that performed integrative single-cell genome and cell surface protein expression profiling of adult acute myeloid leukemia (AML) cases. 

Dec
02

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.